Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in understanding and managing gout.

Talia F Igel1, Svetlana Krasnokutsky2, Michael H Pillinger2

  • 1The Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA; The School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.

F1000Research
|March 31, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy.

Rheumatology (Oxford, England)·2025
Same author

Climate Change, Environmental Risk Factors, and Gout.

Arthritis care & research·2025
Same author

Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial.

Seminars in arthritis and rheumatism·2025
Same author

Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial.

Arthritis care & research·2025
Same author

Some More Equal Than Others: The Divergence of Cardiac Risk in the Use of Nonsteroidal Anti-Inflammatory Drugs Versus Colchicine for Treating and Preventing Gout.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Gout, a common inflammatory arthritis, is often under-diagnosed and under-treated, leading to poor patient outcomes. Recent advances in diagnosis and novel therapies offer hope for improved gout management and quality of life.

Area of Science:

  • Rheumatology
  • Crystal Arthropathies
  • Inflammatory Arthritis

Background:

  • Gout is the most prevalent crystal arthropathy and a primary cause of inflammatory arthritis.
  • It significantly impacts patients' quality of life, functional capacity, morbidity, and mortality.
  • Despite treatment advances, gout remains under-diagnosed and under-treated, with high rates of poor disease control.

Purpose of the Study:

  • To review recent advancements in the diagnosis and management of gout.
  • To discuss novel therapeutic strategies for gout treatment.
  • To highlight potential improvements in patient care and outcomes.

Main Methods:

  • Literature review of recent studies on gout diagnosis and management.
  • Analysis of novel urate-lowering therapies and imaging modalities.
Keywords:
goutgout treatmenturate-lowering therapy

Related Experiment Videos

  • Discussion of updated understanding of gout pathogenesis.

    • Main Results:

    • Gout significantly affects patient morbidity, mortality, and quality of life.
    • A substantial percentage of gout patients experience suboptimal management and persistent hyperuricemia.
    • Novel diagnostic tools and urate-lowering therapies are emerging.

    Conclusions:

    • Recent progress in understanding gout pathogenesis, diagnosis, and treatment offers opportunities for better patient care.
    • Novel therapeutics and diagnostic approaches may lead to improved outcomes for individuals with gout.
    • Addressing under-diagnosis and under-treatment is crucial for effective gout management.